IL110568A - Process for the preparation of S2 (- or) R2 (- endo-bicyclo] 2.2.1 [Heptan-2-ol optically active - Google Patents

Process for the preparation of S2 (- or) R2 (- endo-bicyclo] 2.2.1 [Heptan-2-ol optically active

Info

Publication number
IL110568A
IL110568A IL11056890A IL11056890A IL110568A IL 110568 A IL110568 A IL 110568A IL 11056890 A IL11056890 A IL 11056890A IL 11056890 A IL11056890 A IL 11056890A IL 110568 A IL110568 A IL 110568A
Authority
IL
Israel
Prior art keywords
bicyclo
exo
hept
yloxy
endo
Prior art date
Application number
IL11056890A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL110568A publication Critical patent/IL110568A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL11056890A 1989-11-13 1990-11-06 Process for the preparation of S2 (- or) R2 (- endo-bicyclo] 2.2.1 [Heptan-2-ol optically active IL110568A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1989/005228 WO1991007501A1 (en) 1989-11-13 1989-11-13 Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
IL9626190A IL96261A (en) 1989-11-13 1990-11-06 S)] - 3) -25 (- Exo-bicyclo] 2.2.1 (- Hept-2-Iloxy [-4-methoxyphenyl (- 3,4,5,6-tetrahydropyrimidine-H) 12) -On and R )] -3) -25 (- exo-bicyclo] .2.1 [heft-

Publications (1)

Publication Number Publication Date
IL110568A true IL110568A (en) 1995-10-31

Family

ID=22215375

Family Applications (5)

Application Number Title Priority Date Filing Date
IL9626190A IL96261A (en) 1989-11-13 1990-11-06 S)] - 3) -25 (- Exo-bicyclo] 2.2.1 (- Hept-2-Iloxy [-4-methoxyphenyl (- 3,4,5,6-tetrahydropyrimidine-H) 12) -On and R )] -3) -25 (- exo-bicyclo] .2.1 [heft-
IL110564A IL110564A (en) 1989-11-13 1990-11-06 Derivatives of optical activity of 3-] 3) exo-bicyclo [2.2.1] heptyloxy-4-methoxyphenil [pentanedinitrile) or glutaramide (
IL11056890A IL110568A (en) 1989-11-13 1990-11-06 Process for the preparation of S2 (- or) R2 (- endo-bicyclo] 2.2.1 [Heptan-2-ol optically active
IL11056894A IL110568A0 (en) 1989-11-13 1994-08-04 A process for the preparation of optically active (2s) - or (2r) - endo-bicyclo [2.2.1] heptan-2-ol
IL11056494A IL110564A0 (en) 1989-11-13 1994-08-04 Intermediates eo endo-bicyclo [2.2.1] heptan-2-ol

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL9626190A IL96261A (en) 1989-11-13 1990-11-06 S)] - 3) -25 (- Exo-bicyclo] 2.2.1 (- Hept-2-Iloxy [-4-methoxyphenyl (- 3,4,5,6-tetrahydropyrimidine-H) 12) -On and R )] -3) -25 (- exo-bicyclo] .2.1 [heft-
IL110564A IL110564A (en) 1989-11-13 1990-11-06 Derivatives of optical activity of 3-] 3) exo-bicyclo [2.2.1] heptyloxy-4-methoxyphenil [pentanedinitrile) or glutaramide (

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11056894A IL110568A0 (en) 1989-11-13 1994-08-04 A process for the preparation of optically active (2s) - or (2r) - endo-bicyclo [2.2.1] heptan-2-ol
IL11056494A IL110564A0 (en) 1989-11-13 1994-08-04 Intermediates eo endo-bicyclo [2.2.1] heptan-2-ol

Country Status (27)

Country Link
EP (2) EP0801135A1 (sv)
JP (1) JPH06104661B2 (sv)
KR (1) KR930004654B1 (sv)
CN (1) CN1040423C (sv)
AT (1) ATE158577T1 (sv)
AU (3) AU633157B2 (sv)
CA (1) CA2029705C (sv)
CZ (2) CZ280006B6 (sv)
DE (1) DE69031487T2 (sv)
DK (1) DK0428302T3 (sv)
EG (1) EG19860A (sv)
ES (1) ES2107420T3 (sv)
FI (1) FI105106B (sv)
GR (1) GR3025196T3 (sv)
HU (2) HU220962B1 (sv)
IE (2) IE904059A1 (sv)
IL (5) IL96261A (sv)
MY (1) MY104517A (sv)
NO (1) NO304838B1 (sv)
NZ (1) NZ236037A (sv)
PH (1) PH30255A (sv)
PL (4) PL164176B1 (sv)
PT (1) PT95855B (sv)
RU (1) RU2104306C1 (sv)
WO (1) WO1991007501A1 (sv)
YU (1) YU48413B (sv)
ZA (1) ZA909044B (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007501A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0570593B1 (en) * 1991-12-06 1998-09-09 Shionogi Seiyaku Kabushiki Kaisha Process for producing optically active norborneol
JP3100984B2 (ja) * 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JP3431204B2 (ja) * 1993-04-22 2003-07-28 塩野義製薬株式会社 ノルボルナン型エステル・ヒドロラーゼ
CN1041436C (zh) * 1993-05-07 1998-12-30 佛山市制药一厂 一种稳定冯了性风湿跌打药酒的方法
US5482944A (en) * 1993-07-13 1996-01-09 Pfizer Inc. Pyrimidones and imidazolinones for treatment of shock
JPH1142095A (ja) * 1997-07-25 1999-02-16 Chisso Corp 新規なオキソジシクロペンタジエンの製造方法
KR100479019B1 (ko) * 1998-05-22 2005-08-29 씨제이 주식회사 캐테콜히드라존유도체,이의제조방법및그를함유한약제학적조성물
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
KR20040017246A (ko) 2001-06-29 2004-02-26 니켄 가가쿠 가부시키가이샤 사이클로알케논 유도체
ES2194588B1 (es) * 2001-07-13 2004-10-16 Astur Pharma S.A. Precursores opticamente puros de paroxetina.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261995A (en) * 1979-08-31 1981-04-14 Syntex (U.S.A.) Inc. 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives
US4732853A (en) * 1984-11-21 1988-03-22 President And Fellows Of Harvard College Method of making chiral epoxy alcohols
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
WO1991007501A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents

Also Published As

Publication number Publication date
IE980174A1 (en) 2000-02-23
AU645449B2 (en) 1994-01-13
AU3197993A (en) 1993-04-22
HU215441B (hu) 1999-04-28
HU220962B1 (hu) 2002-07-29
NZ236037A (en) 1992-08-26
EG19860A (en) 1996-03-31
DE69031487D1 (de) 1997-10-30
EP0428302A3 (en) 1992-05-13
PL164202B1 (pl) 1994-06-30
IL110564A (en) 1998-03-10
PL292069A1 (en) 1992-04-21
YU48413B (sh) 1998-07-10
PL164457B1 (pl) 1994-07-29
JPH06104661B2 (ja) 1994-12-21
PT95855B (pt) 1998-01-30
CZ124092A3 (en) 1995-04-12
KR910009622A (ko) 1991-06-28
CA2029705A1 (en) 1991-05-14
IL110564A0 (en) 1994-11-11
FI922142A (fi) 1992-05-12
EP0801135A1 (en) 1997-10-15
PL164176B1 (pl) 1994-06-30
CZ560990A3 (en) 1995-04-12
RU2104306C1 (ru) 1998-02-10
CN1051905A (zh) 1991-06-05
ATE158577T1 (de) 1997-10-15
GR3025196T3 (en) 1998-02-27
AU6653590A (en) 1991-05-16
MY104517A (en) 1994-04-30
PL292070A1 (en) 1992-04-21
FI922142A0 (fi) 1992-05-12
IL110568A0 (en) 1994-11-11
WO1991007501A1 (en) 1991-05-30
PL287727A1 (en) 1992-02-24
CZ280011B6 (cs) 1995-09-13
AU633157B2 (en) 1993-01-21
KR930004654B1 (ko) 1993-06-02
HUT64604A (en) 1994-01-28
CN1040423C (zh) 1998-10-28
ZA909044B (en) 1992-06-24
NO921876D0 (no) 1992-05-12
HU9802988D0 (en) 1999-11-29
AU3292093A (en) 1993-04-22
FI105106B (sv) 2000-06-15
PL165132B1 (pl) 1994-11-30
CZ280006B6 (cs) 1995-09-13
ES2107420T3 (es) 1997-12-01
YU214290A (sh) 1992-12-21
DK0428302T3 (da) 1997-10-13
EP0428302B1 (en) 1997-09-24
PH30255A (en) 1997-02-05
DE69031487T2 (de) 1998-02-05
IL96261A (en) 1996-12-05
IE904059A1 (en) 1991-05-22
IL96261A0 (en) 1991-08-16
NO921876L (no) 1992-07-10
JPH03173871A (ja) 1991-07-29
PT95855A (pt) 1991-09-13
EP0428302A2 (en) 1991-05-22
NO304838B1 (no) 1999-02-22
CA2029705C (en) 1998-11-24

Similar Documents

Publication Publication Date Title
EP0428302B1 (en) Enzymatic resolution of endo-bicycle(2.2.1)-heptan-2-ol and derived pharmaceutical agents
IE63170B1 (en) Calcium independent camp phosphodiesterase inhibitor antidepressant
US5459145A (en) Calcium independent camp phosphodiesterase inhibitor antidepressant
US5270206A (en) Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
WO1991007177A1 (en) Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
US3166571A (en) 1-phenyl-1, 2-cyclopropane dicarboximides
US5395935A (en) Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
US5114960A (en) Substituted isoxazole derivatives
US5461056A (en) Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
JPH07233157A (ja) １，２，３−チアジアゾール誘導体
JPH07233069A (ja) １，２，３−チアジアゾール誘導体を有効成分とする５−リポキシゲナーゼ阻害剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed